Optibetol (Betaxolol)

Betaxolol blocks β1‑adrenergic receptors in the ciliary body, reducing aqueous humor production and thereby decreasing intra‑ocular pressure. Systemically, β1 antagonism lowers heart rate and myocardial contractility, contributing to blood‑pressure reduction.

The prescribed dose of Optibetol is determined by the treating physician based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) once or twice daily, but exact dosing must follow the prescriber’s instructions.

Limited clinical data exist for betaxolol use in pregnancy and lactation. It should only be used when the potential benefit outweighs the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Optibetol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Optibetol (betaxolol) is a selective β1‑blocker, offering a lower risk of bronchospasm compared with non‑selective beta‑blockers like timolol. Its intra‑ocular pressure‑lowering efficacy is comparable, while its side‑effect profile may be more favorable for patients with respiratory concerns.

Store Optibetol at room temperature, below 25 °C, in the original packaging. Protect the bottle from light and moisture, and keep the cap tightly closed when not in use to maintain product stability.

Optibetol is applied as an ophthalmic drop. Wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe allergic reactions (e.g., angioedema), bronchospasm in susceptible individuals, marked bradycardia or heart block, significant hypotension, and visual disturbances such as sudden loss of vision. Patients should seek immediate medical attention if these occur.

Optibetol is contraindicated in patients with known hypersensitivity to betaxolol or any component of the formulation, severe sinus bradycardia, second‑ or third‑degree atrioventricular block, uncontrolled asthma or chronic obstructive pulmonary disease, and in those with cardiogenic shock.